<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18212">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771510</url>
  </required_header>
  <id_info>
    <org_study_id>B110051</org_study_id>
    <nct_id>NCT01771510</nct_id>
  </id_info>
  <brief_title>Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis</brief_title>
  <official_title>A Randomized, Single Center, Double Blind, Parallel, Placebo-controlled Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health &amp; Welfare, Korea</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, Single center, double blind, parallel, placebo-controlled, clinical study of
      efficacy and safety of Chung A Won and placebo for 24 weeks three times a day on the
      improvement of osteoporosis and symptoms in Women's older than 50 patients with osteoporosis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in T-score of bone mineral density(QCT) at 24 weeks</measure>
    <time_frame>baseline, After 24 weeks(Â± 3 days) from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in T-score of bone mineral density(QCT)</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of osteoporosis-related indicators of blood tests</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of ODI(Oswestry Disability Index)</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of QVAS(Quardruple Visual Analog Scale)</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of kupperman index</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of shin-huh symptoms</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of quality of life using SF-36</measure>
    <time_frame>baseline, After 4 weeks, 12 weeks, 24 weeks(endpoint) from the baseline of the trial</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Diseases of the Musculo-skeletal System and Connective Tissue</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Esperimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment) Three times a day, oral administration for 24weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger)</intervention_name>
    <description>Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)
Three times a day, oral administration for 24weeks</description>
    <arm_group_label>Esperimental</arm_group_label>
    <arm_group_label>Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female more than 50 years old

          -  Clnical diagnosis of osteoporosis

        Exclusion Criteria:

          -  Wash out peroid

          -  Subject who takes drugs that may affect the clinical trials (Corticosteroids, a
             nticonvulsants, tranquilizers, antidepressants, hypnotic, diuretic)

          -  Subject who has a chronic liver disease, thyroid disease and chronic renal disease

          -  Pregnant woman

          -  Subject who is not calibrated hypercalcemia/hypocalcemia

          -  Secondary osteoporosis : Subject who takes drugs(Glucocorticoid, Diabetes
             Medications)

          -  Subject who has 60% more fracture risk in FRAX(WHO fracture risk assessment tool)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>hyun Lee</last_name>
    <phone>82-41-521-7578</phone>
    <email>lh2000@dju.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cheonan Oriental Hospital of Daejeon University</name>
      <address>
        <city>Cheonan</city>
        <state>Chungcheongnam-do</state>
        <zip>331-957</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Jo</last_name>
      <phone>82-41-521-7031</phone>
      <email>bluesounds@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>December 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ministry of Health &amp; Welfare, Korea</investigator_affiliation>
    <investigator_full_name>hyun Lee</investigator_full_name>
    <investigator_title>Cheonan Oriental Hospital of Daejeon University</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
